A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis
This is a study of the drug tinidazole for women with recurrent bacterial vaginosis. Half of the participants will get the drug for 10 days, the other half will get the drug for 10 days and then twice a week for 12 weeks.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis|
- Efficacy of oral tinidazole for treatment of recurrent bacterial vaginosis
- Efficacy of oral tinidazole for prevention of recurrent bacterial vaginosis
- Patient satisfaction with tinidazole for recurrent bacterial vaginosis
This study will recruit 60 women with recurrent bacterial vaginosis. These women must have a current infection to be enrolled in the study and have had two other infections within the past 12 months. After initial screening to make sure that the vaginal symptoms are due to bacterial vaginosis and not the results of a different infection, all of the women will receive tinidazole (a drug that is similar to metronidazole) by mouth for 10 days. At the end of the 10 days, patients will be re-examined. Those women who are free of bacterial vaginosis will enter the second phase of the study, where half of the patients will continue to take tinidazole twice a week for twelve weeks and the other half will take no medication. During this time participants will be examined by the study doctor every 4 weeks to see how effective the treatment has been at preventing the recurrence of bacterial vaginosis. At the end of the 12 weeks, women who are still free of bacterial vaginosis will be seen for 3 more visits over 3 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00324142
|United States, California|
|San Francisco, California, United States, 94115|
|Principal Investigator:||Jennifer Gunter, MD||Kaiser Permamente|